Docket No. JARR-244

Total Pages in this Submission

(Only for new nonprovisional applications under 37 CFR 1.53(b))

S. PTO

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C.	111(a) and 37 C.F.R.	1.53(b) is a new utility	patent application for an
invention entitled:			

M		DDS F	d: OR TREATMENT OF HIV OR MALARIA USING COMBINATIONS OF CHLOROQUINE AN INHIBITORS	0 88 0 0 II					
and	invent	ed by	:	8326 8326					
_		<u>——</u>	VARINO	22387					
∟ If a	CONT	INUA	ATION APPLICATION, check appropriate box and supply the requisite information:	-					
	Cont	inua	tion 🗖 Divisional 🗖 Continuation-in-part (CIP) of prior application No.:						
	ch is a Cont ch is a	inuat	ion Divisional Continuation-in-part (CIP) of prior application No.:						
	Cont		ion Divisional Continuation-in-part (CIP) of prior application No.:						
Enc	losed	are:	Application Elements						
•	I. 🛭	Filir	g fee as calculated and transmitted as described below						
2	2. 🛛	Spe	ecification having 35 pages and including the following:						
	a.	×	Descriptive Title of the Invention						
	b.	\boxtimes	Cross References to Related Applications (if applicable)						
	C.		Statement Regarding Federally-sponsored Research/Development (if applicable)						
	d.		Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix						
	e.	×	Background of the Invention						
	f.	×	Brief Summary of the Invention						
	g.	×	Brief Description of the Drawings (if filed)						
	h.	×	Detailed Description						
	i.	×	Claim(s) as Classified Below						
	j.	×	Abstract of the Disclosure						

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. JARR-244

Total Pages in this Submission

Application Elements (Continued)												
3.	X	Dra	wing(s) (when	necessary as	prescribed by	y 35 US	C 113)					
	a.		Formal	Number of S	heets							
	b.	\boxtimes	Informal	Number of S	heets	····	7					
4.		Oat	h or Declaratio	n								
	a.		Newly execut	ed (original or	copy)	☐ Une	executed	t				
	b.		Copy from a	prior applicatio	n (37 CFR 1.	.63(d)) <i>(i</i>	for contin	uation/div	isional appl	lication o	only)	
	C.	☐ With Power of Attorney ☐ Without Power of Attorney ☐ Without Power of Attorney										
	d.		Signed staten	DF INVENTOR nent attached . 1.63(d)(2) an	deleting inver	ntor(s) n	named in	the prior	· applicatio	n,		
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.										
6.		CD	ROM or CD-R	in duplicate, la	arge table or (Comput	er Progr	am (Appe	endix)			
7.		☐ Application Data Sheet (See 37 CFR 1.76)										
8.	Ц	□ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)										
	a.		Computer Re	adable Form (CFR)							
	b.	b. Specification Sequence Listing on:										
	i. CD-ROM or CD-R (2 copies); or											
		ii. 🔲 Paper										
	C.		Statement(s)	Verifying Ident	tical Paper an	nd Comp	outer Re	adable C	ору			
				Ac	companying	Applic	ation Pa	arts				
9.		Assignment Papers (cover sheet & document(s))										
10.		37 CFR 3.73(B) Statement (when there is an assignee)										
11.		English Translation Document (if applicable)										
12.		Information Disclosure Statement/PTO-1449										
13.		Preliminary Amendment										
14.	X	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)										
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)										
16.	X	☑ Certificate of Mailing										
			First Class		Mail (Specify	Label N	lo.): <u>EV</u>	/39805853	35US			

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. JARR-244

Total Pages in this Submission

	Accompanying Application Parts (Continued)						
17.	×	Applicant claims small entity status. See 37 CFR 1.27.					
		☐ (Optional) Small Entity Statement(s) - Specify Number of Statements Submitted:					
18.		Additional Enclosures (please identify below):					
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)					
19.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in					
		this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.					
		Warning Warning					
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.					

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. JARR-244

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED For #Filed #Allowed #Extra Rate Fee \$342.00 **Total Claims** 58 - 20 = 38 \$9.00 X Indep. Claims 9 - 3 = 6 \$43.00 \$258.00 Multiple Dependent Claims (check if applicable) \$0.00 **BASIC FEE** \$385.00 OTHER FEE (specify purpose) \$0.00 **TOTAL FILING FEE** \$985.00 ☐ A check in the amount of to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 50-1402 as described below. A duplicate copy of this sheet is enclosed. \$985.00 as filing fee. Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: 2/20/2004

Eric E. Grondahl (Reg. No. 46,741) McCarter & English LLP

CityPlace I, 185 Asylum Street Hartford, CT 06103-3495

Tel. 860-275-6704

Fax. 860-724-3397

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:) Company And Units To Do Assistant
Andrea Savarino) Group Art Unit: To Be Assigned)) Examiner: To Be Assigned
on METHODS FOR TREATMENT OF HIV OR MALARIA USING COMBINATIONS OF CHLOROQUINE AND PROTEASE INHIBITOR)))
Application Serial Number: To Be Assigned)
Filed On: Herewith) (Docket No. JARR-244)
MAIL STOP: PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-3419 "Express Mail" mailing label number Date of Deposit: February 20, 2004	
I hereby certify that the attached patent app Specification (including 14 pages of Claims, and Application Transmittal Letter; 7 Sheets of Inform being deposited with the United States Postal Servi Addressee" service under 37 C.F.R. 1.10 on the dat MAIL STOP: PATENT APPLICATION, Commiss Alexandria, VA 22313-1450.	I page of Abstract); Utility Patent nal Drawings; and a return postcard; are ce "Express Mail Post Office To te indicated above and is addressed to:
Kristin L. Apuzzo (Typed or printed name of pe	erson mailing paper or fee)
Kuna L Gounge	naner or fee)

Respectfully submitted,

Date: February 20, 2004

Eric E. Grondahl (Reg. No. 46,741)

PTO Correspondence Address:

McCarter & English, LLP CityPlace I, 185 Asylum Street Hartford, CT 06103-3495 Phone: (860) 275-6704

Fax: (860) 724-3397

HARTFORD: 609330.01

97728-00001